) and increased with each P p .069 decade of HCV infection (RR, 2.26; 95% CI, 1.42-3.59;
Hepatitis C virus (HCV) is a major cause of chronic liver disease in the hemophiliac population and is a leading cause of death in this population [1] . More than 90% of hemophiliacs treated with plasma-derived clotting factor concentrates during the 1970s and 1980s became infected with HCV [2] , and 195% have detectable HCV RNA levels, as determined by polymerase chain reaction (PCR) [2] . Unlike those in other risk groups, individuals with hemophilia were infected early in life, with the initiation of clotting factor treatment, usually with the first treatment exposure [3] . Although HCV has been virtually eliminated from concentrates through viral inactivation procedures and recombinant technology, 180% of hemophiliacs 118 years old are HCV infected [4] . Of HCV-infected hemophiliacs, 60% have intermittent or persistent elevation of alanine aminotrans-ferase (ALT) levels [2] , and 20%-25% have developed biopsydocumented cirrhosis [5] .
Because HCV is a heterogeneous virus with a high mutation rate [6] and the immune response ineffective [7] with submaximal cytotoxic T lymphocyte response [8] , the infection is characterized by reactivation, reinfection, and viral persistence [8] . Among individuals with hemophilia, the severity of HCV liver disease may be worsened by other factors, including other hepatitis viruses [9] and human immunodeficiency virus (HIV) [10] .
HIV infection occurred in the hemophiliac population between 1982 and 1983 [10] , up to a decade or more after HCV infection [3] . Whether HIV accelerates HCV liver disease is unknown. The decline in CD4 ϩ T helper lymphocyte number and the defective CD4 ϩ proliferation and apoptosis associated with HIV infection [11] may further impair the ineffective host immune response to HCV. HIV/HCV coinfection is reported to be associated with greater HCV replication [12] , cytokine up-regulation [11] , liver fibrosis [13] , and mortality [1] , despite antiretroviral therapy, than is HCV infection alone. To test our hypothesis that HIV promotes HCV liver disease progression, we evaluated a hemophilic cohort with HCV infection for the development of end-stage liver disease (ESLD).
Patients and Methods
Patients. One hundred fifty-seven patients with hemophilia and HCV infection who were HCV positive in 1978 [2] (including 85 HIV positive and 72 HIV negative) and who were cared for and [2] and HIV infection during 1982-1983 [10] . Since HCV infection occurs with the first exposure to clotting factor [3] , we estimated the onset of HCV infection for each patient as the first year the patient received factor, beginning in 1970 for those born before 1970, or as the year of birth, for those born after 1970. This estimation method was potentially flawed by the underestimation of the duration of HCV infection for those born before 1970 who were treated with plasma. ESLD was defined by the presence of ascites, pedal edema, hepatic encephalopathy, variceal bleeding, jaundice, spontaneous bacterial peritonitis, and/or hepatorenal syndrome. HIV-positive patients were placed on antiretroviral therapy (ART), including highly active ART (HAART), as it became available [12] . One HIV-negative patient and 1 HIV-positive patient (with ESLD) received antiviral treatment for HCV, the latter with ribavirin, which was poorly tolerated. Both have persistently detectable HCV RNA levels, and the HIV-negative patient has not developed ESLD.
Statistical analysis. The relative risks (RRs) and 95% confidence intervals (CIs) for ELSD were estimated by using a proportional hazards model [14] . For these analyses, HIV was a timedependent covariate. An RR significantly different from 1 provided evidence that ESLD was related to the independent variable. For all analyses in this exploratory study, was used to determine P ! .05 statistical significance. Independent variables analyzed in a multiple regression analysis included age at HCV infection, alcohol use, current or past hepatitis B antigen positivity, and HIV infection. The Wilcoxon rank sum test was used to compare the following: immunosuppression, as measured by the nadir CD4 ϩ cell count, between HIV-positive patients with ESLD (in whom the nadir CD4 ϩ cell count typically occurred at ESLD) and those without ELSD; age at development of ESLD between those with and without ESLD; and age at death and duration of HCV infection for those who died, between HIV-positive and HIV-negative patients.
Results
Of the 157 patients, 137 (87.3%) had hemophilia A, and 20 (12.7%) had hemophilia B; 85 (54.1%) were coinfected with HIV. One hundred fifty-one (96.2%) were white, and the remaining 6 (3.8%) were black.
ESLD ϩ cell count 1150 cells/mL or in those who had HIV seroconversion in !3 years. Furthermore, the RR for ESLD in HIV-positive patients with a decrease in CD4 ϩ cell count of 100 cells/mL, adjusting for alcohol use, hepatitis B surface antigenemia, and age at HCV, was not significantly increased (RR, 0.32; 95% CI, 0.08-1.25;
). In 6 of the P p .10 11 patients with ESLD, ESLD occurred at the time of either opportunistic infection or wasting (4 [36%] of 11) or bacterial sepsis (2 [18%] of 11); in 2 patients, central nervous system (CNS) bleeding occurred, both of the latter with anti-VIII inhibitors and HIV-associated thrombocytopenia (р 60,000 cells/ mL). After adjusting for age at HCV infection, we determined that ART was associated with decreased risk of ESLD (RR, 0.14; 95% CI, 0.02-0.95; ). P p .045 The distribution of age at development of ESLD was not significantly different between HIV-positive and HIV-negative patients (median, 43 years and 42 years, respectively; P p , Wilcoxon rank sum test). No patient with hemophilia .578 developed ESLD in !8 years duration of HCV infection. One patient developed hepatocellular carcinoma, an HIV-positive patient with ESLD; the tumor was found at autopsy. Survival after development of ESLD was short: all but 2 patients died within a year of diagnosis of ESLD. The 2 patients who survived longer were an HIV-positive patient on HAART who had wasting and disabling peripheral edema and an HIV-negative patient who had undergone liver transplantation in 1995.
By 1999, 62 HIV-positive and 21 HIV-negative patients had died (higher mortality among HIV-positive than among HIVnegative patients, after adjusting for age at HCV infection; RR, 5.24; 95% CI, 3.07-8.95; ); AIDS was the leading P p .0001 cause of death (table 2), and ESLD was the second leading cause of death (higher mortality among HIV-positive than among HIV-negative patients, after adjusting for age at HCV infection; RR, 3.14; 95% CI, 1.04-9.45;
). Overall, the P p .042 median age at death among the HIV-positive patients (36 years) was lower than that among HIV-negative patients (62 years), with the distribution of age at death significantly different in the 2 groups (  ; table 2 ). The duration of HCV in-P p .0001 fection at the time of death was significantly longer among HIVpositive patients (median, 20 years;
) than among HIV-P p .021 negative patients (median, 18 years).
Discussion
The long-term risk of ESLD among individuals with chronic HCV infection is unknown but of particular concern among adults with hemophilia, 180% of whom have been HCV infected [4] for у20 years [3] (40% of whom are HCV/HIV coinfected) [4] . This study suggests, for the first time, that HIV infection increases the risk of ESLD ∼4-fold over that observed among HIV-negative patients, after adjusting for important cofactors (alcohol abuse, history of hepatitis B surface antigen positivity, and age at HCV infection).
The proportion of HCV-infected hemophilic men in this study who had progressed to ESLD after a mean of 24 years of HCV infection (10%) was much smaller than that predicted in previous studies (20%-30%) [5] , some of which were limited by small sample sizes and short follow-up. Furthermore, in contrast to other at-risk populations, hemophiliacs were exposed (through clotting factor) repeatedly and at a young age to HCV, foreign proteins, antigens, and pathogens, including HIV [10] . Thus, the discrepancy may be due to the significant number of early AIDS-related deaths among HIV/HCV-coinfected hemophilic men who did not live long enough to develop ESLD or, conversely, to the number of men who have wellcompensated cirrhosis, either of which could have underestimated the potential to develop ESLD.
Among HIV-positive patients, ESLD occurred at the time of advanced HIV disease and low CD4 ϩ cell counts. Although ART appears to reduce the risk of ESLD among HIV-positive patients, data are limited by sample size and short follow-up. Moreover, without histologic studies, it is difficult to determine the impact of ART, if any, on liver pathology in the HIV/HCVcoinfected patient. Despite HIV infection and associated HIV immunosuppression in some HIV/HCV-coinfected patients, the rate of hepatocellular carcinoma remains low (0.5%). Whether antiretroviral therapy has prevented any increase in this cancer is unknown but is being followed prospectively. The fact that the single case of hepatocellular carcinoma was diagnosed at autopsy in our study underscores the importance of biopsy or autopsy in diagnosis and detection.
Since there are no noninvasive markers of liver disease progression, liver biopsy remains the major tool to assess severity of liver disease associated with antiretroviral drug toxicity [12] , future liver-based gene therapy, or HIV/HCV coinfection. Even among individuals with hemophilia who were once treated with clotting factor, the risk of bleeding does not appear to be increased [4] .
The mechanism by which HIV infection, which occurred in the hemophiliac population up to a decade or more after initial HCV infection [3] , may increase risk of HCV liver disease progression is unclear. The progressive decline in CD4 ϩ T helper lymphocytes, defective CD4 ϩ proliferation, and CD4 ϩ apoptosis may weaken the already limited immune response to HCV [11] . HIV is also a potent activator of immune response through the up-regulation of the production of cytokines [11] , including interleukin (IL)-6 and transforming growth factor-b, which also are known to promote hepatocyte proliferation and fibrosis [13] . In this regard, a recent study has shown that IL-10 reduces fibrosis in 160% of HCV-infected patients who are unresponsive to interferon [15] . The role of HIV-induced cytokine up-regula-tion in the progression of HCV liver disease may be an important area for future investigation, to develop effective prevention and treatment of this major comorbid condition of hemophilia.
